US Oncology Diagnostics Market, Forecast to 2021

Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories.
Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes.

Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States.

The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.

Research highlights:

  • Annual biopsies and projection estimates for all the cancer types (2016–2021)
  • Revenue forecast by technology type (molecular vs non-molecular) and by intended use (screening, prognosis, diagnosis, therapy selection, and therapy monitoring/management)
  • Key trends and growth opportunities
  • Game-changing companies
  • Disruptive technologies and business models
  • Emerging biomarkers and companion diagnostic development landscape
  • Pricing analysis
  • Epidemiology studies for all cancer types (2016–2021)
  • Strategic recommendations and future outlook of cancer market

Key issues addressed:

  • Which are the cancer types that hold the highest potential in terms of revenue and growth?
  • What are the tests and technologies used to screen, diagnose, and predict therapy in each of the cancers? Where are the new developments taking place?
  • What does the current and prospective competitive landscape look like? What are the approaches being taken by participants to counter competitive threats?
  • How is the landscape for mergers, acquisitions, and collaborations?
  • What are the emerging biomarker opportunities for breast, prostate, cervical, ovarian, lung, and colorectal cancer for developing new tests?
  • Which are the companies that are driving innovation within each cancer type?

Table of Contents

1. Executive Summary
Market Highlights
Scope and Segmentation
Top Economic Motivators for Cancer Testing
Trends Driving Cancer Testing
Examples of Competitive Developments
Future Trends—3 Big Predictions
2. US Oncology Diagnostics Market Overview
Trends/Factors Impacting the Cancer Diagnostics Market
Cancer Market Trends
Market Drivers
Market Restraints
Notable Activities
Top Predictions for the Cancer Diagnostics Market
Objectives—Cancer Moonshot Program
Opportunities—Cancer Moonshot Program
Liquid Biopsy Technology—Investments
3. Overview of Competitors
Competitor Matrix
Competitor Matrix—Technology Used
4. Total Cancer Diagnostics Market
Revenue Forecast
Percent Revenue Forecast by Cancer Segment
Revenue Forecast by Cancer Segment
Total Biopsy Volume Snap Shot
5. Breast Cancer
Breast Cancer—Segmentation
Breast Cancer Incidence and Estimated Biopsies
Growth Opportunities for Technology Providers
Pricing Analysis by Technology Format
Revenue Forecast by Technology Type
Revenue Forecast by Function
Market Share
Market Share Analysis
Key Companies to Watch
Companion Diagnostics—Strategy and Partnerships
Emerging Biomarkers
6. Ovarian Cancer
7. Cervical Cancer
8. Colorectal Cancer
9. Prostate Cancer
10. Lung Cancer
11. Companion Biomarker Opportunities in Drug Development
Summary of Therapeutic Pipeline with Companion Biomarker by Cancer Type
Summary of Therapeutic Pipeline by Phase
Summary of Therapeutic Targets
Summary of Therapeutic Pipeline with Companion Biomarker by Tumor Type
Summary of Tumor Types with Targeted Therapeutics
Companion Diagnostic Targets by Company
Companion Diagnostic Partnerships
Approved Companion Diagnostic Tests—United States
12. Future Outlook and Emerging Opportunities
Keys Factors for Success in Cancer Diagnostic Space
Future Outlook and Emerging Opportunities
13. Appendix
List of Abbreviations
Breast Cancer Epidemiology
Breast Cancer—US Incidence and Forecast, 2016–2021
Breast Cancer—Biomarkers and Assays
Ovarian Cancer Epidemiology
Ovarian Cancer—US Incidence and Forecast, 2016–2021
Ovarian Cancer—Biomarkers and Assays
Cervical Cancer Epidemiology
Cervical Cancer—US Incidence and Forecast, 2016–2021
Cervical Cancer—Biomarkers and Assays
Colorectal Cancer Epidemiology
Colorectal Cancer—US Incidence and Forecast, 2016–2021
Colorectal Cancer—Biomarkers and Assays
Prostate Cancer Epidemiology
Prostate Cancer—US Incidence and Forecast, 2016–2021
Prostate Cancer—Biomarkers and Assays
Lung Cancer Epidemiology
Lung Cancer—US Incidence and Forecast, 2016–2021
Lung Cancer—Biomarkers and Assays
Companies Represented in the Samples Studied
Legal Disclaimer
14. The Frost & Sullivan Story

Infographic



List of Figures & Charts

1. Total Oncology Diagnostics Market: Key Market Drivers, US, 2017–2021
2. Total Oncology Diagnostics Market: Key Market Restraints, US, 2017–2021
3. Total Oncology Diagnostics Market: Competitor Matrix, US, 2016
4. Total Oncology Diagnostics Market: Competitor Matrix, US, 2016
5. Total Oncology Diagnostics Market: Revenue Forecast by Cancer Segment, US, 2016–2021
6. Total Oncology Diagnostics Market: Biopsy Volume Forecast, US, 2015–2021
7. Oncology Diagnostics Market: Breast Cancer—Company Market Share Analysis of Top 4 Participants, US, 2016
8. Oncology Diagnostics Market: Pace of Breast Cancer Companion Diagnostics FDA Approvals, US, 1997–2016
9. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 1997–2016
10. Oncology Diagnostics Market: Emerging Biomarkers for Breast Cancer, US, 2017
11. Oncology Diagnostics Market: Ovarian Cancer—Company Market Share Analysis of Top 5 Participants, US, 2016
12. Oncology Diagnostics Market: Pace of Ovarian Cancer Companion Diagnostics FDA Approvals, US, 2013–2016
13. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2014–2016
14. Oncology Diagnostics Market: Cervical Cancer—Company Market Share Analysis of 3 Participants, US, 2016
15. Oncology Diagnostics Market: Colorectal Cancer—Company Market Share Analysis of Top 5 Participants, US, 2016
16. Oncology Diagnostics Market: Pace of Colorectal Cancer Companion Diagnostics FDA Approvals, US, 2004–2016
17. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2004–2015
18. Oncology Diagnostics Market: Prostate Cancer—Company Market Share Analysis of Top 4 Participants, US, 2016
19. Oncology Diagnostics Market: Lung Cancer—Company Market Share Analysis of Top 3 Participants, US, 2016
20. Oncology Diagnostics Market: Pace of Lung Cancer Companion Diagnostics FDA Approvals, US, 2011–2016
21. Oncology Diagnostics Market: Approved Companion Diagnostic Products, US, 2011–2016
22. Oncology Diagnostics Market: Pipeline of Cancer Biomarkers by Cancer Type, US, 2017
23. Companion Diagnostics Market: Top Cancers with Targeted Therapies, US, 2017
24. Oncology Diagnostics Market: Breast Cancer Epidemiology, US, 2016–2021
25. Oncology Diagnostics Market: Ovarian Cancer Epidemiology, US, 2016–2021
26. Oncology Diagnostics Market: Cervical Cancer Epidemiology, US, 2016–2021
27. Oncology Diagnostics Market: Colorectal Cancer Epidemiology, US, 2016–2021
28. Oncology Diagnostics Market: Prostate Cancer Epidemiology, US, 2016–2021
29. Oncology Diagnostics Market: Lung Cancer Epidemiology, US, 2016–2021


1. Total Oncology Diagnostics Market: Trends Driving Cancer Testing, US, 2016–2021
2. Total Oncology Diagnostics Market: Notable Mergers and Acquisitions, US, 2015 and 2016
3. Total Oncology Diagnostics Market: Notable Mergers and Acquisitions, US, 2016–2017
4. Total Oncology Diagnostics Market: Number of Companies Represented, US, 2016
5. Total Oncology Diagnostics Market: Revenue Forecast, US, 2016–2021
6. Total Oncology Diagnostics Market: Percent Revenue Forecast by Cancer Segment, US, 2016 and 2021
7. Oncology Diagnostics Market: Breast Cancer by Technology, US, 2016
8. Oncology Diagnostics Market: Breast Cancer by Function, US, 2016
9. Oncology Diagnostics Market: Breast Cancer Biopsy Volume, US, 2015–2021
10. Oncology Diagnostics Market: Opportunities for Breast Cancer Market, US, 2016 and 2021
11. Oncology Diagnostics Market: Breast Cancer Revenue Forecast by Technology, US, 2016–2021
12. Oncology Diagnostics Market: Breast Cancer Revenue Forecast by Function, US, 2016–2021
13. Oncology Diagnostics Market: Breast Cancer Market Share, US, 2016
14. Oncology Diagnostics Market: Ovarian Cancer Market by Technology, US, 2016
15. Oncology Diagnostics Market: Ovarian Cancer Market by Function, US, 2016
16. Oncology Diagnostics Market: Ovarian Cancer Biopsy Volume, US, 2015–2021
17. Oncology Diagnostics Market: Opportunities for Ovarian Cancer Market, US, 2016 and 2021
18. Oncology Diagnostics Market: Ovarian Cancer Revenue Forecast by Technology, US, 2016–2021
19. Oncology Diagnostics Market: Ovarian Cancer Revenue Forecast by Function, US, 2016–2021
20. Oncology Diagnostics Market: Ovarian Cancer Market Share, US, 2016
21. Oncology Diagnostics Market: Cervical Cancer by Technology, US, 2016
22. Oncology Diagnostics Market: Cervical Cancer by Function, US, 2016
23. Oncology Diagnostics Market: Cervical Cancer Biopsy Volume, US, 2015–2021
24. Oncology Diagnostics Market: Opportunities for Cervical Cancer Market, US, 2016 and 2021
25. Oncology Diagnostics Market: Cervical Cancer Revenue Forecast by Technology Type, US, 2016–2021
26. Oncology Diagnostics Market: Cervical Cancer Revenue Forecast by Function, US, 2016–2021
27. Oncology Diagnostics Market: Cervical Cancer Market Share, US, 2016
28. Oncology Diagnostics Market: Colorectal Cancer by Technology, US, 2016
29. Oncology Diagnostics Market: Colorectal Cancer by Function, US, 2016
30. Oncology Diagnostics Market: Colorectal Cancer Biopsy Volume, US, 2015–2021
31. Oncology Diagnostics Market: Opportunities for Colorectal Cancer Market, US, 2016 and 2021
32. Oncology Diagnostics Market: Colorectal Cancer Forecast by Technology, US, 2016–2021
33. Oncology Diagnostics Market: Colorectal Cancer Revenue Forecast by Function, US, 2016–2021
34. Oncology Diagnostics Market: Colorectal Cancer Market Share Analysis, US, 2016
35. Oncology Diagnostics Market: Prostate Cancer by Technology, US, 2016
36. Oncology Diagnostics Market: Prostate Cancer by Function, US, 2016
37. Oncology Diagnostics Market: Prostate Cancer Biopsy Volume, US, 2015–2021
38. Oncology Diagnostics Market: Opportunities for Prostate Cancer Market, US, 2016 and 2021
39. Oncology Diagnostics Market: Prostate Cancer Revenue Forecast by Technology, US, 2016–2021
40. Oncology Diagnostics Market: Prostate Cancer Revenue Forecast by Function, US, 2016–2021
41. Oncology Diagnostics Market: Prostate Cancer Market Share Analysis, US, 2016
42. Oncology Diagnostics Market: Lung Cancer by Technology, US, 2016
43. Oncology Diagnostics Market: Lung Cancer by Function, US, 2016
44. Oncology Diagnostics Market: Lung Cancer Biopsy Volume, US, 2015–2021
45. Oncology Diagnostics Market: Opportunities for Lung Cancer, US, 2016 and 2021
46. Oncology Diagnostics Market: Lung Cancer Revenue Forecast by Technology, US, 2016–2021
47. Oncology Diagnostics: Lung Cancer Revenue Forecast by Function, US, 2016–2021
48. Oncology Diagnostics Market: Lung Cancer Market Share Analysis, US, 2016
49. Oncology Diagnostics Market: Development Phases of Companion Products, US, 2016
50. Oncology Diagnostics Market: Drug Diagnostic Biomarker Targets, US, 2016
51. Oncology Diagnostics Market: Selected Solid Tumors, US, 2016
52. Oncology Diagnostics Market: Companion Dx Major Partnerships, US, 2017
53. Oncology Diagnostics Market: Breast Cancer Biomarkers by Function, US, 2017
54. Oncology Diagnostics Market: Ovarian Cancer Biomarkers by Function, US, 2017
55. Oncology Diagnostics Market: Cervical Cancer Biomarkers by Function, US, 2017
56. Oncology Diagnostics Market: Colorectal Cancer Biomarkers by Function, US, 2017
57. Oncology Diagnostics Market: Prostate Cancer Biomarkers by Function, US, 2017
58. Oncology Diagnostics Market: Lung Cancer Biomarkers by Function, US, 2017



Keyword1

Keyword2

Keyword3

Related Research

Release Date : 22-Oct-2015

Region : North America

Release Date : 07-Sep-2015

Region : North America

Release Date : 17-Jul-2015

Region : North America

Release Date : 01-Jul-2015

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.